TY - JOUR
T1 - Systemic amyloidosis associated with chronic lymphocytic leukemia/small lymphocytic lymphoma
AU - Kourelis, Taxiarchis V.
AU - Gertz, Morie
AU - Zent, Clive
AU - Lacy, Martha
AU - Kyle, Robert
AU - Kapoor, Prashant
AU - Zeldenrust, Steven
AU - Buadi, Francis
AU - Witzig, Thomas
AU - Hayman, Suzanne
AU - Lust, John
AU - Russell, Stephen
AU - Lin, Yi
AU - Rajkumar, Vincent S.
AU - Kumar, Shaji
AU - Leung, Nelson
AU - Dingli, David
AU - Dispenzieri, Angela
PY - 2013/5
Y1 - 2013/5
N2 - To clarify the presentation and course of patients with chronic lymphocytic leukemia (CLL) and amyloidosis. Mayo databases were interrogated for patients who carried a diagnosis of amyloidosis and CLL evaluated at Mayo Clinic, Rochester from January 1974 to October 2012. Charts were abstracted and data analyzed. Of the 33 patients identified, 20 (61%) were diagnosed with AL and 13 (39%) with non-AL. Only four patients had immunoglobulin light chain amyloidosis (AL) that could be solely attributed to the CLL clone; another six had both a plasma cell clone and a CLL clone that shared the same light chain. Median overall survival was 15.6 months for patients with AL and 58.1 months for patients with non-AL. For patients with AL management involved chemotherapy targeted toward monoclonal plasma cells, lymphocytes or both, and for patients with non-AL no specific amyloid treatment was administered. AL is a rare complication of CLL, but in this elderly population of patients non-AL is nearly as common. Distinguishing between these two groups is essential since patients with non-AL amyloidosis have better outcomes and they do not require cytotoxic chemotherapy to treat their amyloidosis.
AB - To clarify the presentation and course of patients with chronic lymphocytic leukemia (CLL) and amyloidosis. Mayo databases were interrogated for patients who carried a diagnosis of amyloidosis and CLL evaluated at Mayo Clinic, Rochester from January 1974 to October 2012. Charts were abstracted and data analyzed. Of the 33 patients identified, 20 (61%) were diagnosed with AL and 13 (39%) with non-AL. Only four patients had immunoglobulin light chain amyloidosis (AL) that could be solely attributed to the CLL clone; another six had both a plasma cell clone and a CLL clone that shared the same light chain. Median overall survival was 15.6 months for patients with AL and 58.1 months for patients with non-AL. For patients with AL management involved chemotherapy targeted toward monoclonal plasma cells, lymphocytes or both, and for patients with non-AL no specific amyloid treatment was administered. AL is a rare complication of CLL, but in this elderly population of patients non-AL is nearly as common. Distinguishing between these two groups is essential since patients with non-AL amyloidosis have better outcomes and they do not require cytotoxic chemotherapy to treat their amyloidosis.
UR - http://www.scopus.com/inward/record.url?scp=84876713664&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84876713664&partnerID=8YFLogxK
U2 - 10.1002/ajh.23413
DO - 10.1002/ajh.23413
M3 - Article
C2 - 23508840
AN - SCOPUS:84876713664
SN - 0361-8609
VL - 88
SP - 375
EP - 378
JO - American Journal of Hematology
JF - American Journal of Hematology
IS - 5
ER -